公开(公告)号：US20250127890A1

公开(公告)日：2025-04-24

申请号：US18570121

申请日：2022-10-11

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Inventor： Naushad ALI ,  Mark M. HUYCKE

IPC: A61K39/395 ,  A61K45/06 ,  A61P31/14 ,  C07K16/40 ,  C12N15/113 ,  G01N33/569

Abstract: Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.